May 7, 2025, 21:47

Science is the Cure Research Grant

Kids Beating Cancer invites applications for the 2025 Science is the Cure Research Grant, a two-tiered funding opportunity offering up to $300,000 over three years to advance promising translational research in pediatric blood cancers and solid tumors. This award supports therapeutic development, biomarker discovery, and other impactful innovations aimed at improving outcomes for children with cancer.

Who is eligible?

Applicants must:

Hold an MD, PhD, MD/PhD, or equivalent
Be affiliated with a U.S.-based nonprofit or academic institution
Submit original, unpublished work (updated abstracts may qualify with significant changes)
Demonstrate prior research experience in pediatric cancer
Provide documentation to avoid scientific or budgetary overlap with existing grants
Postdoctoral researchers are eligible to apply

Funding at a glance:

Tier 1: 100,000 USD for 1 year to demonstrate feasibility
Tier 2: 100,000 USD –200,000 USD for up to 2 additional years (invitation-only)
Funds may cover direct costs including personnel, supplies, and equipment
Indirect costs, PR, travel, memberships, and non-research expenses are not allowed

Research focus:

Projects must focus on translational research related to pediatric liquid or solid tumors. This includes studies on therapeutic strategies, biomarker development, or other projects with the potential to impact pediatric patient care within several years.

Key deadlines:

Letter of Intent Due: July 1, 2025
Invitation to Apply: August 1, 2025
Full Proposal Deadline: September 15, 2025
Award Notification: November–December 2025

Where to apply:

All submissions (LOI and full proposals) must be made via ProposalCentral following NIH-style formatting.

Questions?

Sam Azar, COO & VP of Research – [email protected]
Ian Henrich, PhD, Chair, Scientific Advisory Board – [email protected]

biomarker research blood cancers cancer cancer therapy development Childhood Cancer Kids Beating Cancer OncoDaily pediatric cancer research pediatric innovation proposalCENTRAL research grant Science is the Cure solid tumors Translational Oncology

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research